Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Definium Therapeutics, Inc. (DFTX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Healthcare · Biotechnology
New York, NY 10007, United States
definiumtx.com
Price
$42.16
Market Cap
$6.0B
Employees
105
Beta
—
Avg Volume
2,456,547
CEO
Mr. Robert Barrow
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for psychiatric and neurological disorders. Headquartered in New York City, the company applies scientific rigor to psychedelic-based medicine to address underlying disease mechanisms rather than temporary symptom relief. Definium’s lead program centers on DT120, an orally disintegrating tablet formulation of lysergide (LSD) being evaluated in late-stage clinical trials for major depressive disorder and generalized anxiety disorder, where it has received FDA Breakthrough Therapy Designation for GAD. The company is also advancing DT402, the R-enantiomer of MDMA, targeting core symptoms of autism spectrum disorder, particularly social communication challenges. Operating within the pharmaceuticals and biotechnology sectors, Definium Therapeutics occupies a specialized position in the emerging field of evidence-based psychedelic therapeutics, aiming to provide accessible, scalable treatment options across high-burden mental health and brain health indications.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 11 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was Aug 6, 2026.
EPS surprise history — vs analyst consensus · 5 prints of vendor history
-56.0%
Nov '25
-2.0%
Feb '26
+11.1%
Apr '26
-44.9%
May '26
-161.8%
Aug '26
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.55 | $-1.44 -161.8% | — | — |
| May 7, 2026 | $-0.49 | $-0.71 -44.9% | — | — |
| Apr 29, 2026 | $3.69 | $4.10 +11.1% | — | — |
| Feb 26, 2026 | $-0.49 | $-0.50 -2.0% | — | — |
| Nov 6, 2025 | $-0.50 | $-0.78 -56.0% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 6, 2026 | 10-Q | View |
| Aug 6, 2026 | 8-K | View |
| Jun 26, 2026 | 4 | View |
| Jun 26, 2026 | 4 | View |
| Jun 26, 2026 | 4 | View |
| Jun 26, 2026 | 4 | View |
| Jun 26, 2026 | 4 | View |
| Jun 25, 2026 | 144 | View |
| Jun 25, 2026 | 144 | View |
| Jun 25, 2026 | 144 | View |
| Jun 25, 2026 | 144 | View |
| Jun 25, 2026 | 144 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 11, 2026 10:43am (just now)
Current data · timestamped when a report runs
$42.16
Change · Aug 11
-2.99 (-6.62%)
Day Range
$41.90 – $45.52
52-Week Range
$8.70 – $49.70
50-Day MA
$38.27
200-Day MA
$22.20
Volume
28,879.00
Share Structure
Outstanding
104,044,508.00
Float
132,245,296.00
Free Float
127.1%
High free float
— 127.1% of shares trade freely, ~-27.1% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
-20.47
Stock Price: $42.16
EPS (Diluted): -2.06
EPS (Diluted): -2.06
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
11.33
Stock Price: $42.16
Total Equity: $332.33M
Shares: 89,327,608
Total Equity: $332.33M
Shares: 89,327,608
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
—
Market Cap: $5.99B
Total Debt: $40.58M
Cash: $257.84M
EBITDA: N/A
Total Debt: $40.58M
Cash: $257.84M
EBITDA: N/A
EBITDA not available
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$4.4B
Market Cap: $5.99B
Total Debt: $40.58M
Cash: $257.84M
Total Debt: $40.58M
Cash: $257.84M
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
—
Gross Profit: N/A
Revenue: N/A
Revenue: N/A
Missing from API: Gross Profit, Revenue
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
—
Operating Income: -$166.31M
Revenue: N/A
Revenue: N/A
Missing from API: Revenue
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
—
Net Income: -$183.79M
Revenue: N/A
Revenue: N/A
Missing from API: Revenue
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
-55.3%
Net Income: -$183.79M
Total Equity: $332.33M
Total Equity: $332.33M
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
-144.5%
Operating Income: -$166.31M
Tax Rate: 0.0%
Equity: $332.33M
Total Debt: $40.58M
Cash: $257.84M
Tax Rate: 0.0%
Equity: $332.33M
Total Debt: $40.58M
Cash: $257.84M
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
6.29
Current Assets: $419.32M
Current Liabilities: $66.70M
Current Liabilities: $66.70M
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.12
Short-Term Debt: $0.00
Long-Term Debt: $40.58M
Total Debt: $40.58M
Total Equity: $332.33M
Long-Term Debt: $40.58M
Total Debt: $40.58M
Total Equity: $332.33M
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
—
Revenue: N/A
Shares: 89,327,608
Shares: 89,327,608
Missing from API: Revenue
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$3.72
Total Equity: $332.33M
Shares: 89,327,608
Shares: 89,327,608
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$-1.47
Operating CF: -$131.56M
CapEx: $0.00
Shares: 89,327,608
CapEx: $0.00
Shares: 89,327,608
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $42.16
Stock Price: $42.16
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$183.79M
Net Income: -$183.79M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Aug 7, 2026 12:07am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $93.9M | $66.3M | $93.9M | $103.9M | $166.3M |
| Operating Income | -$93.9M | -$66.3M | -$93.9M | -$103.9M | -$166.3M |
| Net Income | -$93.0M | -$56.8M | -$95.7M | -$108.7M | -$183.8M |
| EBITDA | — | — | — | — | — |
| EPS | $-0.85 | $-1.84 | $-0.81 | $-1.54 | $-2.06 |
| EPS (Diluted) | $-0.85 | $-1.84 | $-0.81 | $-1.54 | $-2.06 |
Balance Sheet (Annual)
Last updated: Aug 7, 2026 12:07am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $133.5M | $142.1M | $99.7M | $273.7M | $257.8M |
| Total Current Assets | $137.2M | $146.1M | $103.9M | $281.6M | $419.3M |
| Total Assets | $164.0M | $170.0M | $124.5M | $302.2M | $440.1M |
| Current Liabilities | $10.4M | $17.9M | $32.2M | $38.8M | $66.7M |
| Long-Term Debt | — | — | $14.1M | $21.9M | $40.6M |
| Total Liabilities | $12.3M | $19.1M | $46.4M | $60.7M | $107.8M |
| Total Equity | $151.7M | $150.9M | $78.1M | $241.4M | $332.3M |
| Retained Earnings | -$137.7M | -$194.5M | -$290.2M | -$398.9M | -$582.7M |
Cash Flow (Annual)
Last updated: Aug 7, 2026 12:07am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$45.8M | -$50.1M | -$64.4M | -$79.1M | -$131.6M |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | $-297,000 | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $53.4M | $8.6M | -$42.4M | $174.0M | -$15.9M |
Growth Trends (YoY %)
Last updated: Aug 7, 2026 12:07am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | +29.3% | -41.5% | -10.7% | -60.0% |
| Net Income Growth | +39.0% | -68.6% | -13.5% | -69.1% |
| EBITDA Growth | — | — | — | — |
Industry Benchmarks
Compares DFTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for DFTX — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for DFTX — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for DFTX — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for DFTX — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · four lenses
No community reviews yet for DFTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.525 · a5aac093 · 2026-08-10 20:52:14